

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

ANNOUNCEMENT

AGENCY AGREEMENT WITH GUANGXI MEDICTOP PHARMACEUTICAL CO., LTD.

This announcement is made pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the SFO.

On 22 September 2015, Zhuhai Essex Medipharma entered into the Agency Agreement with Guangxi Medictop, pursuant to which Guangxi Medictop appointed Zhuhai Essex Medipharma as the exclusive sales agent of its products known as Yi Xue An Granules* (伊血安顆粒) in the PRC.

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (“**SFO**”).

On 22 September 2015, Essex Medipharma (Zhuhai) Company Limited* (珠海億勝醫藥有限公司) (“**Zhuhai Essex Medipharma**”), an indirect wholly-owned subsidiary of Essex Bio-Technology Limited (the “**Company**”, and together with its subsidiaries referred as the “**Group**”), entered into an agency agreement (“**Agency Agreement**”) with Guangxi Medictop Pharmaceutical Co., Ltd.* (廣西萬壽堂藥業有限公司) (“**Guangxi Medictop**”). Pursuant to the Agency Agreement, Guangxi Medictop appointed Zhuhai Essex Medipharma as the exclusive sales agent of its products known as Yi Xue An Granules* (伊血安顆粒) in the People’s Republic of China (excluding, for the purpose of the Agency Agreement, the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan) (“**PRC**”).

The Agency Agreement is valid for a period commencing from 22 September 2015 to 31 December 2025. According to the information provided by Guangxi Medictop, Yi Xue An Granules* (伊血安顆粒) is mainly used for treating postpartum lochiorrhea and bleeding or spotting of uterus after induced abortion. The establishment of business relationship with Guangxi Medictop will expand the surgical product line of the Group and enhance sales of the Group's core products, namely Beifuji (貝復濟) and Beifuxin (貝復新), in the market for obstetrics.

The Group is principally engaged in the manufacturing, selling, marketing and distribution of biopharmaceutical products. Guangxi Medictop is principally engaged in the manufacturing, research and development, and sales of Chinese patent medicines (中成藥).

By Order of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 22 September 2015

Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou and Mr. Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Mr. Mauffrey Benoit Jean Marie and Ms. Yeow Mee Mooi.

* *For identification purposes only*